Potaba Shortage: What Providers and Prescribers Need to Know in 2026

If you prescribe Potaba (potassium aminobenzoate) for Peyronie's disease, scleroderma, dermatomyositis, or morphea, you are likely aware that many of your patients struggle to fill their prescriptions. This guide consolidates the current picture on Potaba availability, clinical alternatives, and resources you can offer patients who cannot locate the medication.

Current Availability Status: Not a Formal FDA Shortage, But Practically Scarce

As of 2026, Potaba does not appear on the FDA Drug Shortage Database. The drug is manufactured and distributed through standard supply chains. The availability challenge is structural rather than acute: Potaba is a low-volume niche product that most retail pharmacy chains don't carry because the economics of stocking it at scale don't pencil out for high-traffic chain pharmacies.

From a clinical workflow standpoint, this means patients who receive a Potaba prescription often spend significant time — sometimes days — trying to locate a pharmacy that stocks it. This delay can be a source of frustration and may result in treatment gaps or abandonment.

Why Potaba Is Difficult to Stock at Retail Pharmacies

Low prescription volume: The conditions for which Potaba is prescribed — particularly Peyronie's disease (prevalence approximately 0.5–9% of adult males) and systemic sclerosis (1–25 per 100,000) — represent small patient populations relative to other chronic medications.

Challenging dosing logistics: The standard adult dose of 12 g/day divided into four doses requires dispensing a high volume of 500 mg capsules. A 30-day supply at full dosing requires approximately 720 capsules, making Potaba a high-volume, space-intensive product to stock.

Guideline displacement: The AUA and EAU guidelines do not recommend Potaba as first-line or evidence-supported therapy for Peyronie's disease. As Xiaflex (collagenase clostridium histolyticum) has become more established, Potaba's prescribing base has contracted.

Limited manufacturer base: Potassium aminobenzoate is produced by a small number of manufacturers compared to higher-volume generics, meaning fewer distribution options and potentially longer lead times for wholesaler procurement.

Clinical Alternatives to Consider When Potaba Is Unavailable

For Peyronie's Disease:

Xiaflex (collagenase clostridium histolyticum): FDA-approved for PD with ≥30° curvature. Delivered as 8 intralesional injections over ~6 months. Most robust evidence base for improving curvature.

Pentoxifylline (400–1200 mg/day): Nonspecific PDE inhibitor with antifibrotic and anti-inflammatory properties. Multiple studies demonstrate reduction in plaque size and improvement in subjective and objective parameters. Widely available, generic, and inexpensive.

Tadalafil 5 mg daily: Demonstrated antifibrotic effects in retrospective studies. Also addresses PD-associated erectile dysfunction. Generally well tolerated.

Intralesional verapamil: Office-based alternative for patients not candidates for Xiaflex. Results are variable in controlled trials.

For Scleroderma, Dermatomyositis, and Morphea:

Methotrexate: Used in early diffuse systemic sclerosis and morphea. Anti-inflammatory and immunosuppressive.

Mycophenolate mofetil: Widely used in systemic sclerosis for skin involvement and interstitial lung disease.

Nintedanib (Ofev): FDA-approved for SSc-ILD.

Practical Recommendations for Your Practice

Identify a reliable pharmacy partner. If you prescribe Potaba regularly, establish a relationship with a local independent pharmacy or specialty pharmacy that reliably stocks or can reliably order it. A single phone call from your office staff can save a patient days of frustration.

Mention availability challenges at the point of prescribing. Set patient expectations by noting that Potaba may require a special order. Giving patients 5–7 days of lead time before they run out of an existing supply can prevent treatment gaps.

Refer patients to medfinder.[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop is a service that calls pharmacies on behalf of patients to find which ones can fill a given prescription. Recommending this tool to patients can reduce callbacks and allow your clinical team to focus on care rather than pharmacy coordination.

Document alternatives discussed. If a patient reports they cannot obtain Potaba after a reasonable search, document the clinical discussion about alternatives in the medical record and provide a bridge prescription or referral as appropriate.

Supporting Patients Financially

Potaba's cash price can range from $80–$150 per month, which can be a significant burden for patients on fixed incomes. GoodRx and SingleCare coupons may reduce this cost. Most commercial insurance plans cover potassium aminobenzoate at Tier 2–3. Encourage patients to check their plan's formulary and bring a discount card to the pharmacy.

For a detailed look at savings resources you can share with patients, see How to Help Your Patients Save Money on Potaba: A Provider's Guide.